Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 1.00 |
| ▸ | FAP | Q12884 | 11/20 | 1.00 |
| ▸ | PREP | P48147 | 3/20 | 0.60 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092652 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL3092661 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340775 | 0.92 | DPP4 (0.85) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7932223 | 0.87 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL8228598 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340772 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL7943687 | 0.86 | DPP4 (0.78) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12340760 | 0.85 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL15334549 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12657353 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-07-25 | — | — | US | claimed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4706663-A2 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | Trustees Of Tufts College (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TUFTS COLLEGE (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4144354-B1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TUFTS COLLEGE (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250346646-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4619417-A1 | NANOCONJUGATES CONTAINING PDGFR-BETA LIGANDS AND USES THEREOF | Universitat Autònoma de Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12390422-B2 | Transdermal drug delivery patch, drug delivery system and drug delivery | Passport Technologies, Inc. (US) | 2025-08-19 | — | — | US | disclosed |
| US-8268880-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2011143522-A2 | ENHANCED HOMING AND ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS USING BOROPROLINE COMPOUNDS | DARA BIOSCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20090124559-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE OFFICE OF TECHNOLOGY AND INDUSTRY COLLABORATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124559-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE OFFICE OF TECHNOLOGY AND INDUSTRY COLLABORATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090062235-A1 | Inhibitors of Dipeptidylpeptidase IV | TRUSTEES OF TUFTS COLLEGE (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070072830-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072830-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062235-A1 | Inhibitors of Dipeptidylpeptidase IV | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 9/4885 |
| US-20060063719-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | DPP4 5/4885DPP7 21/4885DPP8 51/4885 |
| US-20250367304-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMB1 | DPP4 442/4885DPP7 363/4885DPP8 313/4885 |
| US-20090124559-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | PREP, DPP4, PEPD | DPP4 2/4885DPP7 8/4885DPP8 13/4885 |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | LEF1, EFNA1, EML4 | DPP4 4643/4885DPP7 4750/4885DPP8 4705/4885 |
| US-20070072830-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | DPP4 5/4885DPP7 21/4885DPP8 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.